**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Kimme Hyrich  
Rik Lories  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)

**Disclaimer:** The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

**Copyright:** © 2020 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

*ARD* is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases*, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

**Editorial**

- 1261** Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?  
*G Herrero-Beaumont, R Largo*

**Viewpoint**

- 1264** Classification criteria: time for a rethink?  
*D Porter, N Basu, S Siebert*

**Views on news**

- 1267** Methotrexate: what are the true risks of treatment?  
*A Strangfeld, C R Burmester*

**Epidemiology**

- 1269** Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group  
*S M Nielsen, H Storgaard, T Ellingsen, B J Shea, G A Wells, V A Welch, D E Furst, M de Wit, M Voshaar, C B Juhl, M Boers, R Escorpizo, T G Woodworth, A Boonen, H Bliddal, L M March, P Tugwell, R Christensen*

- 1277** Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study  
*E Della-Torre, C Campochiaro, G Cavalli, G De Luca, A Napolitano, S La Marca, N Boffini, V Da Prat, G Di Terlizzi, M Lanzillotta, P Rovere Querini, A Ruggeri, G Landoni, M Tresoldi, F Ciceri, AL Zangrillo, F De Cobelli, L Dagna, SARI-RAF Study Group*

- 1286** Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome  
*M Scarsi, S Piantoni, E Colombo, P Airò, D Richini, M Miclini, V Bertasi, M Bianchi, D Bottone, P Civelli, M-S Cotelli, E Damiolini, G Galbassini, D Gatta, M-L Ghirardelli, R Magri, P Malamani, M Mendeni, S Molinari, A Morotti, L Salada, M Turla, A Vender, A Tincani, A Brucato, F Franceschini, R Furloni, L Andreoli*

**Rheumatoid arthritis**

- 1290** Infections in baricitinib clinical trials for patients with active rheumatoid arthritis  
*K L Wintrop, M Harigai, M C Genovese, S Lindsey, T Takeuchi, R Fleischmann, J D Bradley, N L Byers, D L Hyslop, M Issa, A Nishikawa, T P Rooney, S Witt, C L Dickson, J S Smolen, M Dougados*

- 1298** Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN- $\gamma$  treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis  
*X He, Y Yang, M Yao, L Yang, L Ao, X Hu, Z Li, X Wu, Y Tan, W Xing, W Guo, J A Bellanti, S G Zheng, X Xu*

- 1305** Association of the *RPA3-UMAD1* locus with interstitial lung diseases complicated with rheumatoid arthritis in Japanese  
*Y Shirai, S Honda, K Ikari, M Kanai, Y Takeda, Y Kamatani, T Morisaki, E Tanaka, A Kumanogoh, M Harigai, Y Okada*

**Psoriatic arthritis**

- 1310** Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52  
*J S Smolen, P Mease, H Tahir, H Schulze-Koops, I de la Torre, L Li, M Hojnik, C Sapin, M Okada, R Caporali, J Gratacós, P Goupille, S Liu Leage, S Pillai, P Nash*

- 1320** DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study  
*S H M Lam, I T Cheng, E K Li, P Wong, J Lee, R M-L Yip, C-W Yim, S K Ying, M Li, T K Li, A P-W Lee, L-S Tam*

**Spondyloarthritis**

- 1327** Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence  
*B S Koo, J S Oh, S Y Park, J H Shin, C Y Ahn, S Lee, K B Joo, T-H Kim*

MORE CONTENTS ►



Member since 2008

.JM00004

This journal is a member of and subscribes to the principles of the

Committee on Publication Ethics

<http://publicationethics.org/>

When you have finished with this please recycle it

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

## Systemic lupus erythematosus

- 1333** Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities  
*S R Johnson, R Brinks, K H Costenbader, D Daikh, M Mosca, R Ramsey-Goldman, J S Smolen, D Wofsy, D T Boumpas, D L Kamen, D Jayne, R Cervera, N Costedoat-Chalumeau, B Diamond, D D Gladman, B Hahn, F Hiepe, S Jacobsen, D Khanna, K Lerström, E Massarotti, J McCune, G Ruiz-Irastorza, J Sanchez-Guerrero, M Schneider, M Urowitz, G Bertias, B F Hoyer, N Leuchten, C Tani, S K Tedeschi, Z Touma, G Schmajuk, B Anic, F Assan, T M Chan, A E Clarke, M K Crow, L Czirják, A Doria, W B Graninger, B Halda-Kiss, S Hasni, P M Izmirly, M Jung, G Kumánovics, X Mariette, I Padjen, J M Pego-Reigosa, J Romero-Diaz, Í Rúa-Figueroa, R Seror, G H Stummvoll, Y Tanaka, M G Tektonidou, C Vasconcelos, E M Vital, D J Wallace, S Yavuz, P L Meroni, M J Fritzler, R Naden, T Dörner, M Aringer*

- 1340** Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial

*H I Brunner, C Abud-Mendoza, D O Viola, I Calvo Penades, D Levy, J Anton, J E Calderon, V G Chasnyk, M A Ferrandiz, V Keltsev, M E Paz Gastanaga, M Shishov, A L Boteanu, M Henrickson, D Bass, K Clark, A Hammer, B N Ji, A Nino, D A Roth, H Struemper, M-L Wang, A Martini, D Lovell, N Ruperto, in collaboration with the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)*

- 1349** Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis

*K Vanarsa, S Soomro, T Zhang, B Strachan, C Pedroza, M Nidhi, P Cicalese, C Gidley, S Dasari, S Mohan, N Thai, V T T Truong, N Jordan, R Saxena, C Putterman, M Petri, C Mohan*


## Autoinflammatory disorders

- 1362** Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial  
*S Ozen, E Ben-Cherit, I Foeldvari, G Amariyo, H Ozdogan, S Vanderschueren, K Marzan, J M Kahlenberg, E Dekker, F De Benedetti, I Koné-Paut*

## Osteoarthritis

- 1370** Serum NT/CT SIRT1 ratio reflects early osteoarthritis and chondrorescence  
 *G Baishon, J Elayyan, O Qiq, E Reich, L Ben-Aderet, L Kandel, A Haze, J Steinmeyer, V Lefebvre, H Zhang, J Elisseeff, Y Henrotin, A Mobasher, M Dvir-Ginzberg*

## Letters

- 1381** Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series  
*A Aouba, A Baldolli, L Geffray, R Verdon, E Bergot, N Martin-Silva, A Justet*
- 1382** COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine  
*E Bozzalla Cassione, G Zanframundo, A Biglia, V Codullo, C Montecucco, L Cavagna*
- 1383** Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis  
 *S Megremis, T D J Walker, X He, W E R Ollier, H Chinoy, L Hampson, I Hampson, J A Lamb*
- 1386** Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19  
*M F König, A H J Kim, M H Scheetz, E R Graef, J W Liew, J Simard, P M Machado, M Gianfrancesco, J Yazdany, D Langguth, P C Robinson, On behalf of the COVID-19 Global Rheumatology Alliance*

## Electronic pages

- e122** Impact of Janus kinase inhibitors on the risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials  
*Y H Lee, G G Song*
- e123** Response to: 'Impact of Janus kinase inhibitors on the risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials' by Lee and Song  
*W Xie, S Xiao, Z Zhang*
- e124** Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA  
*X M E Matthijssen, T W J Huizinga, E Niemantsverdriet, A H M van der Helm-van Mil*

- e125** Mortality has improved in RA, but we must remain vigilant. Response to: 'Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA' by Matthijssen *et al*  
*P B M Poppelaars, L H D van Tuyl, M Boers*
- e126** Comment on editorial 'Pathogenic effector functions of ACPA: where do we stand?'  
*R Holmdahl*
- e127** Response to: 'Comment on editorial 'Pathogenic effector functions of ACPA: where do we stand'' by Holmdahl  
*R Toes, D S Pisetsky*
- e128** On using machine learning algorithms to define clinically meaningful patient subgroups  
*I Pinal-Fernandez, A L Mammen*
- e129** On how to not misuse hierarchical clustering on principal components to define clinically meaningful patient subgroups. Response to: 'On using machine learning algorithms to define clinical meaningful patient subgroups' by Pinal-Fernandez and Mammen  
*A Meyer, L Spielmann, F Séverac*
- e130** Response to: 'On using machine learning algorithms to define clinically meaningful patient subgroups' by Pinal-Fernandez and Mammen  
*O Benveniste, Y Allenbach, B Granger*
- e131** Concerns about the operational definition of remission in 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus  
*Í Rúa Figueroa, C Erausquin*
- e132** Response to: 'Concerns about the operational definition of remission in 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus' by Rúa-Figueroa and Erausquin  
*A Fanouriakis, G Bertsias, D T Boumpas*
- e133** Treatment of systemic lupus erythematosus: don't forget hydroxychloroquine  
*M Michaud, F Catros, S Ancellin, F Gaches*
- e134** Response to: 'Treatment of systemic lupus erythematosus: don't forget hydroxychloroquine' by Michaud *et al*  
*A Fanouriakis, G Bertsias, D T Boumpas*
- e135** Neutrophil extracellular traps and low-density granulocytes are associated with the interferon signature in systemic lupus erythematosus, but not in antiphospholipid syndrome  
*L L van den Hoogen, M van der Linden, L Meyaard, R D E Fritsch-Stork, J A van Roon, T RDJ Radstake*
- e136** Response to: 'Neutrophil extracellular traps and low-density granulocytes are associated with the interferon signature in systemic lupus erythematosus, but not in antiphospholipid syndrome' by van den Hoogen *et al*  
*M J Kaplan, K A Casey*
- e137** Do the salivary glands of patients with systemic sclerosis show ultrasonographic modifications suggestive of Sjögren's syndrome?  
*M Couderc, A Tournadre, S Mathieu, B Pereira, M Soubrier, J J Dubost*
- e138** Sicca: an important manifestation of damage in systemic sclerosis (SSc) and SSc-overlap syndromes. Response to 'Do the salivary glands of patients with systemic sclerosis show ultrasonographic modifications suggestive of Sjögren's syndrome?' by Couderc *et al*  
*M Nikpour*
- e139** Correction: *EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update*